Filing Flows › Comparisons › OBIO vs GIPL
Orchestra BioMed Holdings vs Global Innovative Platforms: OBIO and GIPL compared
Orchestra BioMed Holdings is the larger company: $88K of revenue in its latest quarter (Q2 2026) against $51K for Global Innovative Platforms (Q3 FY26).
Where the money goes: OBIO and GIPL
Orchestra BioMed Holdings (OBIO) · Q2 2026
Orchestra BioMed Holdings, Q2 2026: revenue $88K (-90% year over year), net loss $23.8M, operating cash flow −$19.3M. The chart follows the revenue to costs, profit and cash.
Global Innovative Platforms (GIPL) · Q3 FY26
Global Innovative Platforms, Q3 FY26: revenue $51K, operating margin -476.6%, net loss $242K, operating cash flow −$134K. The chart follows the revenue to costs, profit and cash.
| Orchestra BioMed Holdings (OBIO) | Global Innovative Platforms (GIPL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 FY26 |
| Revenue | $88K | $51K |
| Revenue growth, Y/Y | -90% | — |
| Operating margin | n/m | -476.6% |
| Net earnings | −$23.8M | −$242K |
| Net margin | — | -476.5% |
| Operating cash flow | −$19.3M | −$134K |
Questions
Which is bigger, Orchestra BioMed Holdings or Global Innovative Platforms?
Orchestra BioMed Holdings is the larger company: $88K of revenue in its latest quarter (Q2 2026) against $51K for Global Innovative Platforms (Q3 FY26).
More: Orchestra BioMed Holdings earnings · how Orchestra BioMed Holdings makes money · Global Innovative Platforms earnings · how Global Innovative Platforms makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 10, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.